Victory Capital Management’s Ovid Therapeutics OVID Stock Holding History

Victory Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.2K	Buy	+13,166	New	+$23.5K	﹤0.01%	2357
2020 Q2	–	Sell	-11,874	Closed	-$36K	–	3041
2020 Q1	$36K	Buy	+11,874	New	+$40K	﹤0.01%	2891
2019 Q4	–	Sell	-4,694	Closed	-$15K	–	3072
2019 Q3	$15K	Buy	+4,694	New	+$10.7K	﹤0.01%	3136
2018 Q1	–	Sell	-105,470	Closed	-$1.04M	–	1895
2017 Q4	$1.04M	Buy	105,470 +4,440	+4%	+$40.8K	﹤0.01%	1219
2017 Q3	$866K	Sell	101,030 -29,970	-23%	-$250K	﹤0.01%	1241
2017 Q2	$1.37M	Buy	+131,000	New	+$1.71M	﹤0.01%	1088

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Victory Capital Management's OVID Position: Q1 2026 in Review

Victory Capital Management opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 13,166 shares worth $29.2K. The stake represents ﹤0.01% of the portfolio and ranks #2357 among its holdings. This is a return to the name: Victory Capital Management previously reported a position in OVID as recently as Q1 2020.

Victory Capital Management first reported a position in OVID in Q2 2017 and has held it in 6 quarters since. The position peaked at $1.37M in Q2 2017. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Victory Capital Management held 13,166 shares of Ovid Therapeutics worth $29.2K as of Q1 2026.
Ovid Therapeutics was a new Victory Capital Management position in Q1 2026.
Ovid Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2357 holding.
Victory Capital Management first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 6 quarters since.
Victory Capital Management's Ovid Therapeutics position peaked at $1.37M in Q2 2017.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.